{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:38:48Z","timestamp":1787506728796,"version":"build-2736575974"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>COVID-19 has been a growing global concern in the past four years. Several syndromes associated with this multi-organ viral infection have been observed since the outbreak. According to estimates, 10\u201315% of people with SARS-CoV- infection may have post-COVID-19 syndrome. Even months after infection, common residual signs and symptoms include myalgia, exhaustion, shortness of breath, rapid heartbeat, stroke, and memory and cognitive impairment which can negatively affect survivors\u2019 quality of life and may consequently lead to their death. Therefore, it is necessary to think about potential therapy options for dealing with both short and long-term impacts. Paracetamol (a common analgesic and antipyretic) and Dexketoprofen Trometamol (a non-steroidal anti-inflammatory drug) are used together to relieve post-COVID symptoms like myalgia (muscle pain) and headache. Additionally, to prevent thrombotic events, Rivaroxaban is recommended for 35 days following discharge. Thus an eco-friendly HPLC-DAD technique was developed for simultaneous quantification of Paracetamol, Dexketoprofen Trometamol, and Rivaroxaban which are co-administered for treatment of post-COVID-19 syndrome. The suggested method was found to be linear in the concentration ranges of 3.00\u201345.00\u00a0\u00b5g\/mL, 0.5\u201350.00\u00a0\u00b5g\/mL, and 0.15\u201320.00\u00a0\u00b5g\/mL, and a limit of detection down to 0.531\u00a0\u00b5g\/mL, 0.095\u00a0\u00b5g\/mL and 0.047\u00a0\u00b5g\/mL for Paracetamol, Dexketoprofen Trometamol and Rivaroxaban, respectively. This method was effectively used to quantify the studied drugs in their bulk powder and spiked human plasma with high percentage recoveries (96.55\u201399.46%). The suggested approach was validated per International Conference on Harmonization (ICH) requirements and found to be within the acceptable ranges. The method was developed using Green Analytical Chemistry (GAC) principles, with the solvents used and run time having a significant effect on the method\u2019s greenness. \u201cNon-toxic\u201d ethanol served as the organic modifier in the mobile phase, moreover, the total run time was 12\u00a0min making it suitable for the routine analysis of the mentioned drugs in plasma samples. To get a full image of the method\u2019s greenness profile; two most recent greenness assessment tools, the Green Analytical Procedure Index (GAPI), and the Analytical GREEnness metric (AGREE), were employed, with White Analytical Chemistry (WAC) principles proving its environmental safety.<\/jats:p>","DOI":"10.1038\/s41598-024-75216-4","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T08:02:36Z","timestamp":1730361756000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A sustainable and green HPLC-PDA technique for the simultaneous estimation of Post-COVID-19 syndrome co-administered drugs with greenness and whiteness assessment"],"prefix":"10.1038","volume":"14","author":[{"given":"Passant M.","family":"Medhat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal Mohamed","family":"Fouad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hany H.","family":"Monir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nermine S.","family":"Ghoniem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,31]]},"reference":[{"key":"75216_CR1","unstructured":"Organization, W. H. Listings of WHO\u2019s response to COVID-19. Available online at: URL (2020). https:\/\/www.who.int\/news-room\/detail\/29-06-2020-covidtimeline (accessed October 5, 2020) (2021)."},{"key":"75216_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/brainsci12010059","volume":"12","author":"Y Turana","year":"2021","unstructured":"Turana, Y., Nathaniel, M., Shen, R., Ali, S. & Aparasu, R. R. Citicoline and COVID-19-related cognitive and other neurologic complications. Brain Sci. 12, 59 (2021).","journal-title":"Brain Sci."},{"key":"75216_CR3","unstructured":"Organization W. H."},{"key":"75216_CR4","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.bj.2020.04.007","volume":"43","author":"YC Liu","year":"2020","unstructured":"Liu, Y. C., Kuo, R. L. & Shih, S. R. COVID-19: the first documented coronavirus pandemic in history. Biomed. J. 43, 328\u2013333 (2020).","journal-title":"Biomed. J."},{"key":"75216_CR5","unstructured":"WHO, C. O. World health organization. Air Quality Guidelines for Europe. (2020)."},{"key":"75216_CR6","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1620\/tjem.250.271","volume":"250","author":"S Baloch","year":"2020","unstructured":"Baloch, S., Baloch, M. A., Zheng, T. & Pei, X. The coronavirus disease 2019 (COVID-19) pandemic. Tohoku J. Exp. Med. 250, 271\u2013278 (2020).","journal-title":"Tohoku J. Exp. Med."},{"key":"75216_CR7","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1001\/jamaneurol.2020.1127","volume":"77","author":"L Mao","year":"2020","unstructured":"Mao, L. et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 77, 683\u2013690 (2020).","journal-title":"JAMA Neurol."},{"key":"75216_CR8","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1007\/s00415-020-10285-9","volume":"268","author":"F Cagnazzo","year":"2021","unstructured":"Cagnazzo, F. et al. Neurological manifestations of patients infected with the SARS-CoV-2: a systematic review of the literature. J. Neurol. 268, 2656\u20132665 (2021).","journal-title":"J. Neurol."},{"key":"75216_CR9","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3390\/brainsci11040454","volume":"11","author":"D Nuzzo","year":"2021","unstructured":"Nuzzo, D. et al. Long-term brain disorders in post Covid-19 neurological syndrome (PCNS) patient. Brain Sci. 11, 454 (2021).","journal-title":"Brain Sci."},{"key":"75216_CR10","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.3390\/brainsci10121012","volume":"10","author":"T Rudroff","year":"2020","unstructured":"Rudroff, T., Fietsam, A. C., Deters, J. R., Bryant, A. D. & Kamholz, J. Post-COVID-19 fatigue: potential contributing factors. Brain Sci. 10, 1012 (2020).","journal-title":"Brain Sci."},{"key":"75216_CR11","doi-asserted-by":"publisher","first-page":"471","DOI":"10.5455\/medarh.2021.75.471-474","volume":"75","author":"N Salihefendic","year":"2021","unstructured":"Salihefendic, N., Zildzic, M. & Huseinagic, H. Ischemic vasculitis as a cause of Brain Disorder\u2019s in patients with long covid: Case Report. Med. Arch. 75, 471 (2021).","journal-title":"Med. Arch."},{"key":"75216_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1146\/annurev-med-043021-030635","volume":"74","author":"A Nalbandian","year":"2023","unstructured":"Nalbandian, A., Desai, A. D. & Wan, E. Y. Post-COVID-19 condition. Annu. Rev. Med. 74, 55\u201364 (2023).","journal-title":"Annu. Rev. Med."},{"key":"75216_CR13","doi-asserted-by":"crossref","unstructured":"Mardani, M. Vol. 15 (Brieflands, (2020).","DOI":"10.5812\/archcid.108819"},{"key":"75216_CR14","first-page":"1","volume":"7","author":"TS Mulla","year":"2011","unstructured":"Mulla, T. S., Rao, J. R., Yadav, S. S., Bharekar, V. V. & Rajput, M. P. Development and validation of HPLC method for simultaneous quantitation of Paracetamol and dexketoprofen trometamol in bulk drug and formulation. Pharmacie Globale.\u00a07, 1\u20134 (2011).","journal-title":"Pharmacie Globale"},{"key":"75216_CR15","first-page":"32","volume":"3","author":"JR Rao","year":"2011","unstructured":"Rao, J. R., Mulla, T. S., Bharekar, V. V., Yadav, S. S. & Rajput, M. P. Simultaneous HPTLC determination of paracetamol and dexketoprofen trometamol in pharmaceutical dosage form. Der Pharma Chem. 3, 32\u201338 (2011).","journal-title":"Der Pharma Chem."},{"key":"75216_CR16","first-page":"216","volume":"54","author":"M \u00c7elebier","year":"2016","unstructured":"\u00c7elebier, M., Re\u00e7ber, T., Ko\u00e7ak, E., Alt\u0131n\u00f6z, S. & K\u0131r, S. Determination of rivaroxaban in human plasma by solid-phase extraction\u2013high performance liquid chromatography. J. Chromatogr. Sci. 54, 216\u2013220 (2016).","journal-title":"J. Chromatogr. Sci."},{"key":"75216_CR17","doi-asserted-by":"publisher","first-page":"e0171272","DOI":"10.1371\/journal.pone.0171272","volume":"12","author":"PBM Derogis","year":"2017","unstructured":"Derogis, P. B. M. et al. Determination of rivaroxaban in patient\u2019s plasma samples by anti-xa chromogenic test associated to high performance liquid chromatography tandem Mass Spectrometry (HPLC-MS\/MS). PLoS One. 12, e0171272 (2017).","journal-title":"PLoS One"},{"key":"75216_CR18","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0140-6736(21)02392-8","volume":"399","author":"E Ramacciotti","year":"2022","unstructured":"Ramacciotti, E. et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet. 399, 50\u201359 (2022).","journal-title":"Lancet"},{"key":"75216_CR19","first-page":"49","volume":"3","author":"D Pokharkar","year":"2011","unstructured":"Pokharkar, D. et al. Stability indicating RP-HPLC-PDA method for simultaneous determination of Dexketoprofen Trometamol and Paracetamol from tablet dosage form. Der Pharmacia Letter.\u00a03, 49\u201357 (2011).","journal-title":"Der Pharmacia Letter"},{"key":"75216_CR20","first-page":"365","volume":"3","author":"L Kothapalli","year":"2011","unstructured":"Kothapalli, L. et al. Simultaneous spectrophotometric estimation of Paracetamol and dexketoprofen trometamol in pharmaceutical dosage form, Der Pharm. Der Pharma Chem. 3, 365\u2013371 (2011).","journal-title":"Der Pharma Chem."},{"key":"75216_CR21","first-page":"1","volume":"2","author":"B Seshamamba","year":"2017","unstructured":"Seshamamba, B. & Sekaran, C. Spectrophotometric quantification of direct factor xa inhibitor, rivaroxaban, in raw and tablet dosage form. Glob Drugs th. 2, 1\u20138 (2017).","journal-title":"Glob Drugs th."},{"key":"75216_CR22","first-page":"21","volume":"7","author":"BSV Seshamamba","year":"2017","unstructured":"Seshamamba, B. S. V. & Sekaran, C. B. Spectrophotometric Analysis for the quantification of Rivaroxaban in Bulk and Tablet Dosage Form. Int. J. Med. Pharm. Sci. 7, 21\u201334 (2017).","journal-title":"Int. J. Med. Pharm. Sci."},{"key":"75216_CR23","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1080\/22297928.2017.1385420","volume":"7","author":"RI El-Bagary","year":"2017","unstructured":"El-Bagary, R. I., Elkady, E. F., Farid, N. A. & Youssef, N. F. A validated Spectrophotometric Method and Thermodynamic studies for the determination of Cilostazol and Rivaroxaban in Pharmaceutical preparations using Fe-Phenanthroline System. Anal. Chem. Lett. 7, 676\u2013688 (2017).","journal-title":"Anal. Chem. Lett."},{"key":"75216_CR24","first-page":"1546","volume":"3","author":"BSV Seshamamba","year":"2014","unstructured":"Seshamamba, B. S. V., Satyanarayana, P. V. V. & Sekaran, C. B. Application of stability indicating HPLC method with UV detector to the analysis of rivaroxaban in bulk and tablet dosage form. Chem. Sci. Trans. 3, 1546\u20131554 (2014).","journal-title":"Chem. Sci. Trans."},{"key":"75216_CR25","doi-asserted-by":"publisher","first-page":"23155","DOI":"10.1039\/c4ra00744a","volume":"4","author":"NR Ramisetti","year":"2014","unstructured":"Ramisetti, N. R. & Kuntamukkala, R. Development and validation of a stability indicating LC-PDA-MS\/MS method for separation, identification and characterization of process related and stress degradation products of rivaroxaban. RSC Adv. 4, 23155\u201323167 (2014).","journal-title":"RSC Adv."},{"key":"75216_CR26","first-page":"1503","volume":"34","author":"ME Walter","year":"2015","unstructured":"Walter, M. E. et al. Development and validation of a stability-indicating RP-HPLC method for the determination of rivaroxaban in pharmaceutical formulations. Lat Am. J. Pharm. 34, 1503\u20131510 (2015).","journal-title":"Lat Am. J. Pharm."},{"key":"75216_CR27","first-page":"65","volume":"5","author":"MD Hadagali","year":"2015","unstructured":"Hadagali, M. D. Determination of rivaroxaban in pure, pharmaceutical formulations and human plasma samples by RP-HPLC. Int. J. Adv. Pharm. Anal. 5, 65\u201368 (2015).","journal-title":"Int. J. Adv. Pharm. Anal."},{"key":"75216_CR28","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1556\/1326.2016.28.3.05","volume":"28","author":"E Souri","year":"2016","unstructured":"Souri, E., Mottaghi, S., Zargarpoor, M., Ahmadkhaniha, R. & Jalalizadeh, H. Development of a stability-indicating HPLC method and a dissolution test for rivaroxaban dosage forms. Acta Chromatogr. 28, 347\u2013361 (2016).","journal-title":"Acta Chromatogr."},{"key":"75216_CR29","first-page":"379","volume":"13","author":"M Elesbao Walter","year":"2017","unstructured":"Elesbao Walter, M. et al. Micellar Electrokinetic Capillary Method for the Analysis of Rivaroxaban and its correlation with RP\u2013LC method and Bioassay. Curr. Anal. Chem. 13, 379\u2013385 (2017).","journal-title":"Curr. Anal. Chem."},{"key":"75216_CR30","doi-asserted-by":"publisher","first-page":"212","DOI":"10.5958\/0974-360X.2018.00040.9","volume":"11","author":"B Arous","year":"2018","unstructured":"Arous, B., Al-Mardini, M. A., Ghazal, H. & Al-Lahham, F. Stability-Indicating Method for the determination of Rivaroxaban and its Degradation products using LC-MS and TLC. RJPT. 11, 212\u2013220 (2018).","journal-title":"RJPT"},{"key":"75216_CR31","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1039\/C9RA07825H","volume":"10","author":"P Alam","year":"2020","unstructured":"Alam, P. et al. Ecofriendly densitometric RP-HPTLC method for determination of rivaroxaban in nanoparticle formulations using green solvents. RSC Adv. 10, 2133\u20132140 (2020).","journal-title":"RSC Adv."},{"key":"75216_CR32","doi-asserted-by":"publisher","first-page":"9397","DOI":"10.1039\/C4AY01871K","volume":"6","author":"\u0130 S\u00fcsl\u00fc","year":"2014","unstructured":"S\u00fcsl\u00fc, \u0130., \u00c7elebier, M. & Alt\u0131n\u00f6z, S. Electrochemical behaviour investigation and square-wave voltammetric determination of rivaroxaban in pharmaceutical dosage forms. Anal. Methods. 6, 9397\u20139403 (2014).","journal-title":"Anal. Methods"},{"key":"75216_CR33","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.talanta.2018.01.013","volume":"181","author":"J P\u0142otka-Wasylka","year":"2018","unstructured":"P\u0142otka-Wasylka, J. A new tool for the evaluation of the analytical procedure: Green Analytical Procedure Index. Talanta. 181, 204\u2013209 (2018).","journal-title":"Talanta"},{"key":"75216_CR34","doi-asserted-by":"publisher","first-page":"10076","DOI":"10.1021\/acs.analchem.0c01887","volume":"92","author":"F Pena-Pereira","year":"2020","unstructured":"Pena-Pereira, F., Wojnowski, W. & Tobiszewski, M. AGREE\u2014Analytical GREEnness metric approach and software. Anal. Chem. 92, 10076\u201310082 (2020).","journal-title":"Anal. Chem."},{"key":"75216_CR35","doi-asserted-by":"publisher","first-page":"116223","DOI":"10.1016\/j.trac.2021.116223","volume":"138","author":"PM Nowak","year":"2021","unstructured":"Nowak, P. M., Wietecha-Pos\u0142uszny, R. & Pawliszyn, J. White Analytical Chemistry: an approach to reconcile the principles of Green Analytical Chemistry and functionality. TrAC Trends Anal. Chem. 138, 116223 (2021).","journal-title":"TrAC Trends Anal. Chem."},{"key":"75216_CR36","unstructured":"Guideline, I. H. T. Validation of analytical procedures: text and methodology. Q2 (R1) 1, 05 (2005)."},{"key":"75216_CR37","unstructured":"Pharmacopeia, U. in The United States Pharmacopeia-The National Formulary, The United States Pharmacopeial Convention, Rockville, MD. 195\u2013197."},{"key":"75216_CR38","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1177\/0310057X1103900214","volume":"39","author":"J Van der Westhuizen","year":"2011","unstructured":"Van der Westhuizen, J., Kuo, P., Reed, P. & Holder, K. Randomised controlled trial comparing oral and intravenous Paracetamol (acetaminophen) plasma levels when given as preoperative analgesia. Anaesth. Intensive Care. 39, 242\u2013246 (2011).","journal-title":"Anaesth. Intensive Care"},{"key":"75216_CR39","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2165\/00003088-200140040-00002","volume":"40","author":"MJ Barbanoj","year":"2001","unstructured":"Barbanoj, M. J., Antonijoan, R. M. & Gich, I. Clinical pharmacokinetics of dexketoprofen. Clin. Pharmacokinet. 40, 245\u2013262 (2001).","journal-title":"Clin. Pharmacokinet."},{"key":"75216_CR40","doi-asserted-by":"publisher","first-page":"e5491","DOI":"10.1002\/bmc.5491","volume":"36","author":"J Qian","year":"2022","unstructured":"Qian, J., Gu, S. & Yan, Y. j. determination of rivaroxaban in rat plasma by ultra-high\u2010performance liquid chromatography\u2013Q\u2010Orbitrap high\u2010resolution mass spectrometry and its application to a pharmacokinetic study. Biomed. Chromatogr. 36, e5491 (2022).","journal-title":"Biomed. Chromatogr."},{"key":"75216_CR41","doi-asserted-by":"publisher","first-page":"108105","DOI":"10.1016\/j.microc.2022.108105","volume":"183","author":"A Hemdan","year":"2022","unstructured":"Hemdan, A., Magdy, R., Farouk, M. & Fares, N. V. Central composite design as an analytical optimization tool for the development of eco-friendly HPLC-PDA methods for two antihypertensive mixtures containing the angiotensin receptor blocker Valsartan: greenness assessment by four evaluation tools. Microchem J. 183, 108105 (2022).","journal-title":"Microchem J."},{"key":"75216_CR42","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1021\/cr068359e","volume":"107","author":"LH Keith","year":"2007","unstructured":"Keith, L. H., Gron, L. U. & Young, J. L. Green analytical methodologies. Chem. Rev. 107, 2695\u20132708 (2007).","journal-title":"Chem. Rev."},{"key":"75216_CR43","doi-asserted-by":"publisher","first-page":"19318","DOI":"10.1038\/s41598-023-46636-5","volume":"13","author":"HM Nagieb","year":"2023","unstructured":"Nagieb, H. M., Abdelwahab, N. S., Abdelrahman, M. M., Zaazaa, H. E. & Ghoniem, N. S. Greenness assessment of UPLC\/MS\/MS method for determination of two antihypertensive agents and their harmful impurities with ADME\/TOX profile study. Sci. Rep. 13, 19318 (2023).","journal-title":"Sci. Rep."},{"key":"75216_CR44","doi-asserted-by":"publisher","first-page":"110733","DOI":"10.1016\/j.microc.2024.110733","volume":"201","author":"NM Habib","year":"2024","unstructured":"Habib, N. M., Tony, R. M., AlSalem, H. S., Algethami, F. K. & Gamal, M. Evaluation of the greenness, whiteness, and blueness profiles of stability indicating HPLC method for determination of denaverine hydrochloride and benzyl alcohol in pharmaceuticals. Microchem J. 201, 110733 (2024).","journal-title":"Microchem J."},{"key":"75216_CR45","doi-asserted-by":"publisher","first-page":"109511","DOI":"10.1016\/j.microc.2023.109511","volume":"195","author":"FK Algethami","year":"2023","unstructured":"Algethami, F. K. & Gamal, M. Development of a simple, eco-friendly HPLC-DAD method for tulathromycin analysis: ensuring stability and assessing greenness. Microchem J. 195, 109511 (2023).","journal-title":"Microchem J."},{"key":"75216_CR46","doi-asserted-by":"crossref","unstructured":"Prajapati, P. B., Radadiya, K. & Shah, S. A. Quality risk management based: analytical quality by design approach to eco-friendly and versatile chromatography method for simultaneous estimation of multiple fixed-dose-combination products of anti-diabetic drugs. J. Pharm. Innov. 17, 1\u201318 (2020).","DOI":"10.1007\/s12247-020-09506-5"},{"key":"75216_CR47","doi-asserted-by":"crossref","unstructured":"Prajapati, P., Shah, H. & Shah, S. A. Implementation of QRM and DoE-based quality by design approach to VEER chromatography method for simultaneous estimation of multiple combined dosage forms of Paracetamol. J. Pharm. Innov. 17, 1\u201317 (2020).","DOI":"10.1007\/s12247-020-09490-w"},{"key":"75216_CR48","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1039\/D0AY02169E","volume":"13","author":"M Gamal","year":"2021","unstructured":"Gamal, M., Naguib, I. A., Panda, D. S. & Abdallah, F. F. Comparative study of four greenness assessment tools for selection of greenest analytical method for assay of hyoscine N-butyl bromide. Anal. Methods. 13, 369\u2013380 (2021).","journal-title":"Anal. Methods"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75216-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75216-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75216-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T08:03:52Z","timestamp":1730361832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75216-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,31]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["75216"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-75216-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,31]]},"assertion":[{"value":"25 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26222"}}